- Home
- CURR vs TNYA Comparison
CURR vs TNYA Comparison
Compare CURR & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- TNYA
- Stock Information
- Founded
- CURR 2013
- TNYA 2016
- Country
- CURR Singapore
- TNYA United States
- Employees
- CURR N/A
- TNYA N/A
- Industry
- CURR Business Services
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- CURR Consumer Discretionary
- TNYA Health Care
- Exchange
- CURR Nasdaq
- TNYA Nasdaq
- Market Cap
- CURR 74.0M
- TNYA 73.8M
- IPO Year
- CURR N/A
- TNYA 2021
- Fundamental
- Price
- CURR $1.05
- TNYA $0.60
- Analyst Decision
- CURR Strong Buy
- TNYA Strong Buy
- Analyst Count
- CURR 1
- TNYA 5
- Target Price
- CURR $3.50
- TNYA $8.60
- AVG Volume (30 Days)
- CURR 8.5M
- TNYA 3.0M
- Earning Date
- CURR 08-11-2025
- TNYA 08-07-2025
- Dividend Yield
- CURR N/A
- TNYA N/A
- EPS Growth
- CURR N/A
- TNYA N/A
- EPS
- CURR N/A
- TNYA N/A
- Revenue
- CURR $43,386,858.00
- TNYA N/A
- Revenue This Year
- CURR N/A
- TNYA N/A
- Revenue Next Year
- CURR $21.53
- TNYA N/A
- P/E Ratio
- CURR N/A
- TNYA N/A
- Revenue Growth
- CURR N/A
- TNYA N/A
- 52 Week Low
- CURR $0.33
- TNYA $0.36
- 52 Week High
- CURR $7.08
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- TNYA 52.95
- Support Level
- CURR N/A
- TNYA $0.54
- Resistance Level
- CURR N/A
- TNYA $0.70
- Average True Range (ATR)
- CURR 0.00
- TNYA 0.06
- MACD
- CURR 0.00
- TNYA -0.00
- Stochastic Oscillator
- CURR 0.00
- TNYA 40.74
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.